Skip to main content
. 2019 Aug 5;19:208. doi: 10.1186/s12935-019-0928-5

Fig. 7.

Fig. 7

Estimated half-maximal inhibitory concentration (IC50) of high risk group and low risk group for antitumor durgs: axitinib, cisplatin, gemcitabine, pazopanib, sorafenib and temsirolimus